Emergent BioSolutions Inc. announced new purchase orders worth $29 million from an international government partner for medical countermeasures against smallpox, anthrax, and botulism. This reflects the increasing importance of defense preparedness worldwide. The company expects to receive $26 million in 2025, in addition to over $100 million in sales generated year to date. Recent commitments by NATO members to increase defense expenditures support Emergent’s international expansion. Emergent specializes in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

CEO Joe Papa highlighted the importance of international partnerships in addressing multiple threat segments. The company’s products help governments respond to emergencies and protect the public from potential threats. Emergent’s growth trajectory is supported by increasing demand outside the U.S., recent international procurements, and commitments by NATO members to raise defense expenditures. The company aims to protect and save lives by delivering solutions for health threats like smallpox, anthrax, and opioid overdose emergencies.

Forward-looking statements by Emergent BioSolutions Inc. caution that actual results could differ from expectations due to inaccurate assumptions or unknown risks. Investors are advised to consider risk factors identified in the company’s periodic reports filed with the U.S. Securities and Exchange Commission. For more information, visit the company’s website and follow them on social media. Contact Executive Vice President, CFO Richard S. Lindahl for investor inquiries and Vice President, Communications Assal Hellmer for media inquiries.

Read more at GlobeNewswire: Emergent BioSolutions Secures $29 Million in MCM Product